Outcomes of Lymphoma Among American Adolescent and Young Adult Patients Varied by Health Insurance-A SEER-based Study.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
received:
07
02
2021
accepted:
06
08
2021
pubmed:
7
9
2021
medline:
20
4
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Impacts of health insurance status on survival outcomes among adolescent and young adult (AYA, 15 to 39 years of age) patients with lymphoma in the United States are insufficiently known. This study aimed to clarify associations between health insurance status and overall survival (OS) estimates in this population. We examined 18 Surveillance, Epidemiology, and End Results registries in the United States and analyzed American AYA patients with lymphoma diagnosed during January 2007 and December 2016. Health insurance status was categorized, and Kaplan-Meier and multifactor Cox regressions were adopted using hazard ratio and 95% confidence interval. Probable baseline confounding was modulated by multiple propensity score. A total of 21,149 patients were considered; ~28% were 18 to 25 years old, and 63.5% and 7.5% had private and no insurance, respectively. Private insurance rates increased in the 18 to 25 age group (60.1% to 6.1%, P<0.001) following the 2010 Patient Protection and Affordable Care Act (ACA), and lymphoma survival rates improved slightly 1 to 5 years postdiagnosis. Five-year OS rates decreased with age (93.9%, 90.4%, and 87.0% at 15 to 17, 18 to 25, and 26 to 39, respectively) and differed among insurance conditions (81.7%, 79.2%, 89.2%, and 92.0% for uninsured, Medicaid, insured, and insured/no specifics, respectively). Risk of death was significantly higher for those with Medicaid or no insurance than for those with private insurance in multiple propensity score-adjusted models (hazard ratio [95% confidence interval]=1.07 [1.03-1.12]), independent of stage at diagnosis. No or insufficient insurance was linked to poor OS in our sample in exposure-outcome association analysis. Insurance coverage and health care availability may enhance disparate outcomes of AYAs with cancer. The ACA has improved insurance coverage and survival rates for out sample. Nevertheless, strategies are needed to identify causality and eliminate disparities.
Identifiants
pubmed: 34486562
doi: 10.1097/MPH.0000000000002314
pii: 00043426-202203000-00029
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e403-e412Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pollock BH, Birch JM. Registration and classification of adolescent and young adult cancer cases. Pediatr Blood Cancer. 2008;50(suppl):1090–1093.
Shaw PH, Reed DR, Yeager N, et al. Adolescent and Young Adult (AYA) Oncology in the United States: a specialty in its late adolescence. J Pediatr Hematol Oncol. 2015;37:161–169.
Kahn JM, Ozuah NW, Dunleavy K, et al. Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes. Blood Adv. 2017;1:1945–1958.
Tai E, Pollack LA, Townsend J, et al. Differences in non-Hodgkin lymphoma survival between young adults and children. Arch Pediatr Adolesc Med. 2010;164:218–224.
Mogensen H, Modig K, Tettamanti G, et al. Survival after childhood cancer-social inequalities in high-income countries. Front Oncol. 2018;8:485.
Chao C, Chiu V, Xu L, et al. Survival differences by race/ethnicity and neighborhood socioeconomic status in adolescents and young adults diagnosed with non-Hodgkin lymphoma. J Adolesc Young Adult Oncol. 2015;4:76–83.
Puckett Y, Ta A. Socioeconomic factors impact inpatient mortality in pediatric lymphoma patients. Cureus. 2016;8:e624.
Kahn JM, Keegan TH, Tao L, et al. Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer. 2016;122:2723–2730.
Keegan TH, DeRouen MC, Parsons HM, et al. Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: a population-based study. Cancer Epidemiol Biomarkers Prev. 2016;25:264–273.
Biasoli I, Castro N, Delamain M, et al. Lower socioeconomic status is independently associated with shorter survival in Hodgkin lymphoma patients—an analysis from the Brazilian Hodgkin Lymphoma Registry. Int J Cancer. 2018;142:883–890.
Rosenberg AR, Kroon L, Chen L, et al. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer. 2015;121:1279–1286.
Aizer AA, Falit B, Mendu ML, et al. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014;32:2025–2030.
Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45:992–1005.
Pulte D, Gondos A, Brenner H. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer. 2009;115:4973–4979.
Gupta S, Baxter NN, Hodgson D, et al. Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: an IMPACT Cohort Study. Cancer Med. 2020;9:6933–6945.
Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9:222–231.
Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58:9–31.
James SL, Castle CD, Dingels ZV, et al. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. Inj Prev. 2020;26(supp 1):i96–i114.
Martin S, Ulrich C, Munsell M, et al. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist. 2007;12:816–824.
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994.
Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control. 2008;19:841–858.
Che G, Huang B, Xie Z, et al. Trends in incidence and survival in patients with melanoma, 1974-2013. Am J Cancer Res. 2019:9:1396–1414.
Sun H, Ma H, Hong G, et al. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010. Sci Rep. 2014;4:6747.
Zheng G, Wang Y, Zhao Y, et al. Clinicopathological features, treatment strategy, and prognosis of primary non-Hodgkin’s lymphoma of the duodenum: A SEER Database Analysis. Can J Gastroenterol Hepatol. 2020;2020:9327868.
Zhou H, Huang Y, Qiu Z, et al. Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: a pan-cancer analysis of the SEER database. Int J Cancer. 2018;143:1569–1577.
Spreeuwenberg MD, Bartak A, Croon MA, et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care. 2010;48:166–174.
Zhu H, Lu B. Multiple comparisons for survival data with propensity score adjustment. Comput Stat Data Anal. 2015;86:42–51.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.
Adams H, Adams HH, Jackson C, et al. Evaluating extent of resection in pediatric glioblastoma: a multiple propensity score-adjusted population-based analysis. Childs Nerv Syst. 2016;32:493–503.
McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32:3388–3414.
McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9:403–425.
DeRouen MC, Parsons HM, Kent EE, et al. Sociodemographic disparities in survival for adolescents and young adults with cancer differ by health insurance status. Cancer Causes Control. 2017;28:841–851.
Manchikanti L, Caraway DL, Parr AT, et al. Patient Protection and Affordable Care Act of 2010: reforming the health care reform for the new decade. Pain Physician. 2011;14:E35–E67.
Sayadi M, Zare N, Attar A, et al. Improved Landmark Dynamic Prediction Model to assess cardiovascular disease risk in on-treatment blood pressure patients: a simulation study and post hoc analysis on SPRINT data. Biomed Res Int. 2020;2020:2905167.
Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. JAMA Surg. 2013;148:516–523.
Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28:4800–4809.
Comber H, De Camargo Cancela M, Haase T, et al. Affluence and private health insurance influence treatment and survival in non-Hodgkin’s lymphoma. PLoS One. 2016;11:e0168684.
Martijn HA, Njuguna F, Olbara G, et al. Influence of health insurance status on paediatric non-Hodgkin’s lymphoma treatment in Kenya. BMJ Paediatr Open. 2017;1:e000149.
Polite BN, Griggs JJ, Moy B, et al. American Society of Clinical Oncology policy statement on medicaid reform. J Clin Oncol. 2014;32:4162–4167.
Keegan TH, Tao L, DeRouen MC, et al. Medical care in adolescents and young adult cancer survivors: what are the biggest access-related barriers. J Cancer Surviv. 2014;8:282–292.
Smith AW, Bellizzi KM, Keegan TH, et al. Health-related quality of life of adolescent and young adult patients with cancer in the United States: the Adolescent and Young Adult Health Outcomes and Patient Experience study. J Clin Oncol. 2013;31:2136–2145.
Rosenberg AR, Macpherson CF, Kroon L, et al. Rethinking adherence: a proposal for a new approach to risk assessment. J Adolesc Young Adult Oncol. 2013;2:83–86.
Gorey KM, Luginaah IN, Holowaty EJ, et al. Mediation of the effects of living in extremely poor neighborhoods by health insurance: breast cancer care and survival in California, 1996 to 2011. Int J Equity Health. 2013;12:6.
Lillie-Blanton M, Hoffman C. The role of health insurance coverage in reducing racial/ethnic disparities in health care. Health Aff (Millwood). 2005;24:398–408.
Shankaran V, Jolly S, Blough D, et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30:1608–1614.
Ubel PA, Abernethy AP, Zafar SY. Full disclosure—out-of-pocket costs as side effects. N Engl J Med. 2013;369:1484–1486.
Yabroff KR, Dowling EC, Guy GP Jr, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259–267.
Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534–2542.
Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). 2013;27:80–1, 149.
Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist. 2013;18:381–390.
Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117:180–189.
Wu XC, Lund MJ, Kimmick GG, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2012;30:142–150.
Benjamins MR, Whitman S. Relationships between discrimination in health care and health care outcomes among four race/ethnic groups. J Behav Med. 2014;37:402–413.
Joshua TV, Rizzo JD, Zhang MJ, et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010;116:3469–3476.
Parker LJ, Hunte H, Ohmit A. Discrimination in health care: correlates of health care discrimination among Black males. Am J Mens Health. 2017;11:999–1007.
Truong TH, Pole JD, Bittencourt H, et al. Access to hematopoietic stem cell transplantation among pediatric patients with acute lymphoblastic leukemia: a population-based analysis. Biol Blood Marrow Transplant. 2019;25:1172–1178.
Chae DH, Nuru-Jeter AM, Adler NE, et al. Discrimination, racial bias, and telomere length in African-American men. Am J Prev Med. 2014;46:103–111.
Krieger N, Davey Smith G. “Bodies count,” and body counts: social epidemiology and embodying inequality. Epidemiol Rev. 2004;26:92–103.
Tehranifar P, Neugut AI, Phelan JC, et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev. 2009;18:2701–2708.
Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol. 2007;166:646–655.
Bradley CJ, Gardiner J, Given CW, et al. Cancer, medicaid enrollment, and survival disparities. Cancer. 2005;103:1712–1718.